Skip to main content

Table 2 Pharmacokinetics of 213Bi-DOTATATE at 10, 30, 60 and 120 min post injection (p.i.) in CA20948 tumour-bearing animals, expressed in mean %IA/g ± SD, n = 7

From: Influence of tumour size on the efficacy of targeted alpha therapy with 213Bi-[DOTA0,Tyr3]-octreotate

Uptake (%IA/g)

10 min p.i.

30 min p.i.

60 min p.i.

120 min p.i.

Tumour

19.6 ± 6.6

15.1 ± 6.6

12.7 ± 1.6

11.2 ± 5.4

Muscle

3.1 ± 0.8

1.5 ± 0.8

1.4 ± 1.9

0.2 ± 0.2

Kidney

51.5 ± 16.6

26.0 ± 3.3

15.0 ± 1.5

18.0 ± 1.9

Pancreas

3.6 ± 0.2

3.1 ± 0.4

1.5 ± 0.3

1.2 ± 0.2

Liver

2.0 ± 0.2

1.0 ± 0.1

0.2 ± 0.04

0.2 ± 0.03

Blood

7.1 ± 1.0

2.6 ± 0.4

0.3 ± 0.2

0.07 ± 0.04

Spleen

2.0 ± 0.2

1.1 ± 0.4

0.2 ± 0.05

0.2 ± 0.04

Adrenal

3.4 ± 0.7

2.2 ± 0.8

0.6 ± 0.1

0.4 ± 0.1

Femur

2.4 ± 0.2

1.4 ± 0.2

0.6 ± 0.1

0.2 ± 0.04

  1. %IA/g = mean percentage of total injected radioactivity per gram tissue